Singapore Cancer Registry (Singapore) **

Database Contact Data

Hazimah Razak
Quality Service Manager
Ministry of Health, Singapore
Email: MOH_QSM@moh.gov.sg

Alternate Contact

Email: HPB_SERVICENRDO@hpb.gov.sg

References of Studies Using/Describing Database

1. Thomas CE, Adibi JJ, Kuipers AL, Diergaarde B, Luu HN, Jin A, Koh WP, Gao YT, Adams-Haduch J, Wang R, Lokshin A. Soluble CD137 and risk of hepatocellular carcinoma: nested case–control studies in cohorts in Shanghai and Singapore. British Journal of Cancer. 2023 Jun 15;128(11):2081-8.

2. Peres MA, Huihua L, Antunes JL, Perea LM, Iyer NG, Peres KG. Time trend and Age-Period-Cohort analysis of potentially HPV-related oral and pharyngeal cancer incidence in Singapore between 1968 and 2017. Oral Oncology. 2023 Jan 1;136:106272.

3. Yu YC, Paragomi P, Jin A, Wang R, Schoen RE, Koh WP, Yuan JM, Luu HN. Dietary nonstarch polysaccharide intake and risk of colorectal cancer: findings from the Singapore Chinese health study. Cancer research communications. 2022 Oct 31;2(10):1304-11.

4. Soo R, Mery L, Bardot A, Kanesvaran R, Keong TC, Pongnikorn D, Prasongsook N, Hutajulu SH, Irawan C, Ab Manan A, Thiagarajan M. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. ESMO open. 2022 Oct 1;7(5):100560.

5. Htun HL, Lian W, Wong J, Tan EJ, Foo LL, Ong KH, Lim WY. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017. Cancer Epidemiology. 2022 Aug 1;79:102175.

6. Sheng LT, Jiang YW, Pan A, Koh WP. Dietary total antioxidant capacity and mortality outcomes: The Singapore Chinese Health Study. European Journal of Nutrition. 2022 Aug;61(5):2375-82.

7. Lei M, Adambekov S, Edwards RP, Wang R, Yuan JM, Kalix E, Lopa S, Linkov F. Endometrial cancer risk factors in Singapore Chinese: a prospective cohort study. Annals of Epidemiology. 2022 Jul 1;71:9-14.

8. Paragomi P, Wang R, Jin A, Yu YC, Brand RE, Sheng LT, Pan A, Koh WP, Yuan JM, Luu H. Composite dietary antioxidant index and the risk of pancreatic cancer: Findings from a prospective cohort study. Cancer Research. 2022 Jun 15;82(12_Supplement):3667-.

9. Yu YC, Paragomi P, Wang R, Jin A, Schoen RE, Sheng LT, Pan A, Koh WP, Yuan JM, Luu HN. Composite dietary antioxidant index and the risk of colorectal cancer: findings from the Singapore Chinese Health Study. International Journal of Cancer. 2022 May 15;150(10):1599-608.

10. Tan TH, Zheng H, Cheo T, Tey J, Soon YY. Risk of Stroke in Nasopharyngeal Cancer Survivors: A National Registry-Based Population Cohort Study. Neurology. 2022 Jan 11;98(2):e115-24.

12/21/20 Victorian Cancer Biobank (VCB) profile uploaded

VCB is one of the largest multi-center collection facilities of its kind in the world, collecting tissue and blood from donors at 26 public & private hospitals in metropolitan Melbourne. VCB has an open-door policy to public and private investigators or companies that have an ethically approved research project. It is customer-focused with an archival collection of >400,000 biospecimens in various storage formats and can support prospective collections.

Victorian Cancer Biobank (VCB) (Australia)

Database Contact Data

Wayne Ng, PhD 
General Manager
Victorian Cancer Biobank
615 St. Kilda Rd
Melbourne, Victoria 3004 
AUSTRALIA
Phone: +61 3 9514 6179
Email: Wayne.Ng@cancervic.org.au

Alternate Contact

1. Enquiries
Project Manager
Victorian Cancer Biobank
615 St Kilda Rd
Melbourne, Victoria 3004
AUSTRALIA
Phone: +61 3 9514 6186
Email: VCBEnquiries@cancervic.org.au

2. If you cannot reach the database manager, you may contact the Biobank by completing the contact form at: https://viccancerbiobank.org.au/services/enquire

References of Studies Using/Describing Database

1. Joyce R, Pascual R, Heitink L, Capaldo BD, Vaillant F, Christie M, Tsai M, Surgenor E, Anttila CJ, Rajasekhar P, Jackling FC. Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers. Nature Cell Biology. 2024 Jan 12:1-5.

2. Li R, Liu S, Yeo K, Edwards S, Li MY, Santos R, Kianpour Rad S, Wu F, Maddern G, Young J, Tomita Y. Circulating SFRP5 levels are elevated in colorectal cancer and correlate with overall survival in stage II-III disease. medRxiv. 2024:2024-03.

3. Tan T, Mouradov D, Lee M, Gard G, Hirokawa Y, Li S, Lin C, Li F, Luo H, Wu K, Palmieri M. Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancer. Cell Reports Medicine. 2023 Dec 19;4(12).

4. Lam GT, Sorvina A, Martini C, Prabhakaran S, Ung BS, Lazniewska J, Moore CR, Beck AR, Hopkins AM, Johnson IR, Caruso MC. Altered endosomal-lysosomal biogenesis in melanoma. Neoplasia. 2023 Sep 1;43:100924.

5. Weeden CE, Gayevskiy V, Marceaux C, Batey D, Tan T, Yokote K, Ribera NT, Clatch A, Christo S, Teh CE, Mitchell AJ. Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. Cancer Cell. 2023 May 8;41(5):837-52.

6. Leong TL, Aloe C, Aujla S, Wang H, Gayevskiy V, Asselin-Labat ML, Gray LA, Steinfort D, Bozinovski S. Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling. Frontiers in Oncology. 2023 Mar 13;13:1150349.

7. Cain SA, Pope B, Mangiola S, Mantamadiotis T, Drummond KJ. Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression. BMC cancer. 2023 Mar 7;23(1):216.

8. Coombes C, Horikawa K, Jain S, Jiang S, Lim JH, Saxena K, Shadbolt B, Smyth L, Tobin J, Talaulikar D. Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis. Pathology. 2023 Feb 1;55(1):104-12.

9. Shewell LK, Day CJ, Hippolite T, De Bisscop X, Paton JC, Paton AW, Jennings MP. Serum Neu5Gc biomarkers are elevated in primary cutaneous melanoma. Biochem Biophys Res Commun. 2023 Jan 29;642:162-166.

10. Boys, Emma, Jia Liu, Zhaoxiang Cai, Zainab Noor, Karen L. Mackenzie, Adel Aref, Erin Sykes et al. Pan-cancer diagnostic proteomic signature of tissue-of-origin (TOO) using data-independent acquisition mass spectrometry (DIA-MS) from 1289 human tissue samples. Journal of Clinical Oncology. 2023;41(16): 3120-3120.

Subscribe to